James E. Flynn‘s Deerfield Management has disclosed a stake in Syros Pharmaceuticals Inc (NASDAQ:SYRS), a biotechnology company recently gone public. According to a recent filing with the Securities and Exchange Commission, the fund holds 2.09 million shares, which account for approximately 8.97% of Syros Pharmaceuticals’ common stock.
Syros Pharmaceuticals Inc (NASDAQ:SYRS) has developed a gene control platform that analyzes the DNA of patients in order to identify new targets for gene control medicines. The company went public at the end of June in an IPO priced at $12.50 per share, although initially it aimed between $14 and $16 a share. Syros Pharmaceuticals offered 4.6 million shares and options for an additional 600,000 shares for their underwriters, totaling gross proceeds of $57.5 million. The company will use the funds to finance further development of its SY-1425 candidate for the treatment of acute myelogenous leukemia and myelodysplastic syndrome, and the SY-1365 candidate designed to treat acute leukemia.
No other hedge funds followed by Insider Monkey have yet disclosed a position in Syros Pharmaceuticals Inc (NASDAQ:SYRS).
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Deerfield Mgmt | 0 | 628,566 | 0 | 628,566 | 628,566 | 2.69% |
| Deerfield Management Company | 0 | 2,095,220 | 0 | 2,095,220 | 2,095,220 | 8.97% |
| Deerfield Mgmt III | 0 | 1,466,654 | 0 | 1,466,654 | 1,466,654 | 6.28% |
| Deerfield Special Situations Fund | 0 | 628,566 | 0 | 628,566 | 628,566 | 2.69% |
| Deerfield Private Design Fund III | 0 | 1,466,654 | 0 | 1,466,654 | 1,466,654 | 6.28% |
| James E. Flynn | 0 | 2,095,220 | 0 | 2,095,220 | 2,095,220 | 8.97% |
Page 1 of 14 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. ) *
Syros Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
87184Q107
(CUSIP Number)
July 6, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page 1 of 11 Pages)
__________________
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 2 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 628,566 (1) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 628,566 (1) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 628,566 (1) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.69% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
__________________
(1) Comprised of Common Stock held by Deerfield Special Situations Fund, L.P. of which Deerfield Mgmt, L.P. is the general partner.
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 3 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Management Company, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 2,095,220 (2) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 2,095,220 (2) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,095,220 (2) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.97% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
__________________
(2) Comprised of Common Stock held by Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P. of which Deerfield Management Company, L.P. is the investment advisor.
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 4 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt III, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 1,466,654 (3) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 1,466,654 (3) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,466,654 (3) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.28% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
__________________
(3) Comprised of Common Stock held by Deerfield Private Design Fund III, L.P. of which Deerfield Mgmt III, L.P. is the general partner.
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 5 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Special Situations Fund, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 628,566 | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 628,566 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 628,566 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.69% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 6 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Private Design Fund III, L.P. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 1,466,654 | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 1,466,654 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,466,654 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.28% | ||
| 12. | TYPE OF REPORTING PERSON* PN | ||
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 7 of 11 |
| 1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) James E. Flynn | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) o (b) ý | |
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION United States | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 2,095,220 (4) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 2,095,220 (4) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,095,220 (4) | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | o | |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.97% | ||
| 12. | TYPE OF REPORTING PERSON* IN | ||
__________________
(4) Comprised of Common Stock held by Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P.
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 8 of 11 |
| Item 1(a). | Name of Issuer: | |
| Syros Pharmaceuticals, Inc. | ||
| Item 1(b). | Address of Issuer’s Principal Executive Offices: | |
| 620 Memorial Drive, Suite 300 Cambridge, MA 02139 | ||
| Item 2(a). | Name of Person Filing: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Private Design Fund III, L.P. | ||
| Item 2(b). | Address of Principal Business Office, or if None, Residence: | |
| James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Private Design Fund III, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017 | ||
| Item 2(c). | Citizenship: | |
| Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P. – Delaware limited partnerships; James E. Flynn – United States citizen | ||
| Item 2(d). | Title of Class of Securities: | |
| Common Stock, par value $0.001 per share | ||
| Item 2(e). | CUSIP Number: | |
| 87184Q107 | ||
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
| (a) | o | Broker or dealer registered under Section 15 of the Exchange Act. | |
| (b) | o | Bank as defined in Section 3(a)(6) of the Exchange Act. | |
| (c) | o | Insurance company as defined in Section 3(a)(19) of the Exchange Act. | |
| (d) | o | Investment company registered under Section 8 of the Investment Company Act. |
| (e) | o | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 9 of 11 |
| (f) | o | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); | |
| (g) | o | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); |
| (h) | o | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; |
| (i) | o | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; |
| (j) | o | A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); |
| |
| (k) | o | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). |
If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________
| Item 4. | Ownership. |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
| (a) | Amount beneficially owned**: | ||
| Deerfield Mgmt, L.P. – 628,566 shares Deerfield Mgmt III, L.P. – 1,466,654 shares Deerfield Management Company, L.P. – 2,095,220 shares Deerfield Special Situations Fund, L.P. – 628,566 shares Deerfield Private Design Fund III, L.P. – 1,466,654 shares James E. Flynn – 2,095,220 shares | |||
| (b) | Percent of class**: | ||
| Deerfield Mgmt, L.P. – 2.69% Deerfield Mgmt III, L.P. – 6.28% Deerfield Management Company, L.P. – 8.97% Deerfield Special Situations Fund, L.P. – 2.69% Deerfield Private Design Fund III, L.P. – 6.28% James E. Flynn – 8.97% |
| (c) | Number of shares as to which such person has**: | ||||
| (i) | Sole power to vote or to direct the vote: | All Reporting Persons – 0 | |||
| (ii) | Shared power to vote or to direct the vote: | Deerfield Mgmt, L.P. – 628,566 shares Deerfield Mgmt III, L.P. – 1,466,654 shares Deerfield Management Company, L.P. – 2,095,220 shares Deerfield Special Situations Fund, L.P. – 628,566 shares Deerfield Private Design Fund III, L.P. – 1,466,654 shares James E. Flynn – 2,095,220 shares | |||
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 10 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 10 of 11 |
| (iii) | Sole power to dispose or to direct the disposition of: | All Reporting Persons – 0 | |||
| (iv) | Shared power to dispose or to direct the disposition of: | Deerfield Mgmt, L.P. – 628,566 shares Deerfield Mgmt III, L.P. – 1,466,654 shares Deerfield Management Company, L.P. – 2,095,220 shares Deerfield Special Situations Fund, L.P. – 628,566 shares Deerfield Private Design Fund III, L.P. – 1,466,654 shares James E. Flynn – 2,095,220 shares |
**See footnotes on cover pages which are incorporated by reference herein.
| Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following o.
| | |
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
| | N/A |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
| | N/A |
| Item 8. | Identification and Classification of Members of the Group. |
If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.
| | See Exhibit B |
| Item 9. | Notice of Dissolution of Group. |
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
| | N/A |
| Item 10. | Certifications. |
“By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11.”
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 11 of 14 – SEC Filing
| CUSIP No. | 87184Q107 | 13G | Page 11 of 11 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Date: July 6, 2016
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 12 of 14 – SEC Filing
Exhibit List
Exhibit A. Joint Filing Agreement.
Exhibit B. Item 8 Statement.
Exhibit C. Power of Attorney (1).
(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Editas Medicine, Inc. filed with the Securities and Exchange Commission on February 2, 2016 by Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield Private Design Fund, L.P., Deerfield Private Design International, L.P., Deerfield PDI Financing, L.P., Deerfield PDI Financing II, L.P., Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield International Master Fund, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Breaking Stick Holdings, LLC, Deerfield Private Design Fund III, L.P. and James E. Flynn.
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 13 of 14 – SEC Filing
Exhibit A
Joint Filing Agreement
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock, par value $0.001 of Syros Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 14 of 14 – SEC Filing
Exhibit B
Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.
Follow Syros Pharmaceuticals Inc.
Follow Syros Pharmaceuticals Inc.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.